Endogenous thyrotropin and triiodothyronine concentrations in individuals with thyroid cancer.
BACKGROUND
Thyroid hormone suppression therapy is associated with decreased recurrence rates and improved survival in patients with differentiated thyroid cancer. Recently higher baseline thyrotropin (TSH) levels have been found to be associated with a postoperative diagnosis of differentiated thyroid cancer. Our objective was to confirm whether preoperative TSH levels were higher in patients who were diagnosed with differentiated thyroid cancer after undergoing thyroidectomy, compared with patients who were found to have benign disease. We also sought to determine whether thyroid hormone levels were lower in the patients with malignancy.


METHODS
The study was a retrospective analysis of a prospective study. The study setting was the General Clinical Research Center of an Academic Medical Center. Participants were 50 euthyroid patients undergoing thyroidectomy. Thyroxine, triiodothyronine (T(3)), and TSH levels were documented in patients prior to their scheduled thyroidectomy. Following thyroidectomy, patients were divided into those with a histologic diagnosis of either differentiated thyroid cancer or benign disease. Preoperative thyroid profiles were correlated with patients' postoperative diagnoses.


RESULTS
All patients had a normal serum TSH concentration preoperatively. One-third of the group was diagnosed with thyroid cancer as a result of their thyroidectomy. These patients had a higher serum TSH level (mean = 1.50 mIU/L, CI 1.22-1.78 mIU/L) than patients with benign disease (mean = 1.01 mIU/mL, CI 0.84-1.18 mIU/L). There was a greater risk of having thyroid cancer in patients with TSH levels in the upper three quartiles of TSH values, compared with patients with TSH concentrations in the lowest quartile of TSH values (odd ratio = 8.7, CI 2.2-33.7). Patients with a thyroid cancer diagnosis also had lower T(3) concentrations measured by liquid chromatography tandem mass spectrometry (mean = 112.6 ng/dL, CI 103.8-121.4 ng/dL) than did patients with a benign diagnosis (mean 129.9 ng/dL, CI 121.4-138.4 ng/dL).


CONCLUSIONS
These data confirm that higher TSH concentrations, even within the normal range, are associated with a subsequent diagnosis of thyroid cancer in individuals with thyroid abnormalities. This further supports the hypothesis that TSH stimulates the growth or development of thyroid malignancy during its early or preclinical phase. We also show for the first time that patients with thyroid cancer also have lower T(3) levels than patients with benign disease.
Jonklaas
Jacqueline
J
Division of Endocrinology, Georgetown University Medical Center, Washington, District of Columbia 20007, USA. jj@bc.georgetown.edu
Nsouli-Maktabi
Hala
H
Soldin
Steven J
SJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D011446:Prospective Studies; D012189:Retrospective Studies; D013964:Thyroid Neoplasms / Q000097:blood*; D013965:Thyroidectomy / Q000379:methods; D013972:Thyrotropin / Q000097:blood*; D014284:Triiodothyronine / Q000097:blood*
D014284:Triiodothyronine; D013972:Thyrotropin
J Clin Endocrinol Metab. 1996 Dec;81(12):4318-23
8954034
Am Surg. 2005 Oct;71(10):874-8
16468540
J Clin Endocrinol Metab. 2007 Jul;92(7):2610-5
17426094
Lancet. 1954 Apr 17;266(6816):812-3
13153121
Clin Endocrinol (Oxf). 2005 Jun;62(6):672-8
15943828
J Clin Endocrinol Metab. 2006 Nov;91(11):4295-301
16868053
Cancer. 1998 Sep 1;83(5):1012-21
9731906
Thyroid. 2006 Dec;16(12):1229-42
17199433
J Clin Endocrinol Metab. 2008 Apr;93(4):1224-30
18230665
J Clin Endocrinol Metab. 2002 Feb;87(2):489-99
11836274
Int J Radiat Oncol Biol Phys. 1988 Jun;14(6):1063-75
2454902
Ann Med. 2002;34(7-8):554-64
12553495
Arch Surg. 1998 Apr;133(4):419-25
9565123
Surgery. 1999 Dec;126(6):1070-6; discussion 1076-7
10598190
Thyroid. 1995 Feb;5(1):35-40
7787431
J Clin Endocrinol Metab. 1976 Feb;42(2):395-8
177443
J Nucl Med. 1980 Aug;21(8):733-7
7400828
J Am Coll Surg. 2007 May;204(5):764-73; discussion 773-5
17481480
Eur J Surg Oncol. 1994 Dec;20(6):613-21
7995409
Clin Chim Acta. 2004 May;343(1-2):185-90
15115693
Annu Rev Physiol. 2000;62:439-66
10845098
Cancer. 1995 Dec 1;76(11):2312-8
8635037
J Clin Endocrinol Metab. 2006 Nov;91(11):4253-5
17088441
J Clin Endocrinol Metab. 2007 Dec;92(12):4575-82
17911171
Am J Med. 1994 Nov;97(5):418-28
7977430
Am J Surg. 1990 Oct;160(4):344-7
2221232
Nat Clin Pract Endocrinol Metab. 2005 Nov;1(1):32-40
16929364
Adv Ther. 2007 May-Jun;24(3):510-6
17660159
Surgery. 1985 May;97(5):539-46
2986305
Thyroid. 1998 Sep;8(9):737-44
9777742
J Clin Endocrinol Metab. 1981 Jan;52(1):23-8
6256403
J Clin Endocrinol Metab. 2008 Mar;93(3):809-14
18160464
JAMA. 2008 Feb 20;299(7):769-77
18285588
J Clin Endocrinol Metab. 1999 Mar;84(3):829-34
10084556
Arch Surg. 1988 May;123(5):569-74
3358683
J Clin Endocrinol Metab. 1980 Oct;51(4):915-20
7419673